ABOUT US

history

Every Journey Starts With a Step

We started ours in 1989 when our founders, Randy W. Hamilton and Lorin K. Johnson, PhD, realized the need for more effective gastrointestinal solutions. Since then, Salix hasn’t stopped moving forward.

1989

- Salix Pharmaceuticals is founded in Sunnyvale, California

1990

- COLAZAL® (balsalazide disodium) is licensed

1996

- XIFAXAN® (rifaximin) is licensed

2000

- Operations move to Raleigh, North Carolina
- COLAZAL® (balsalazide disodium) receives FDA approval

2004

- XIFAXAN® (rifaximin) 200 mg receives FDA approval

2006

- MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) receives FDA approval

2008

- APRISO® (mesalamine granules) receives FDA approval
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for opioid-induced constipation (OIC) in adults with advanced illness when other medicines for constipation have not worked well enough

2009

- OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) receives FDA approval

2010

- XIFAXAN® (rifaximin) 550 mg receives FDA approval for hepatic encephalopathy (HE)

2013

- UCERIS® (budesonide) extended-release tablets receives FDA approval
- GIAZO® (mesalamine) receives FDA approval

2014

- Salix acquires Santarus
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for OIC in adults with chronic non-cancer pain

2015

- UCERIS® (budesonide) rectal foam receives FDA approval
- XIFAXAN® (rifaximin) 550 mg receives FDA approval for irritable bowel syndrome with diarrhea (IBS-D)
- Valeant acquires Salix
- Operations begin moving to Bridgewater, New Jersey, our current location

2016

- Salix launches RELISTOR® (methylnaltrexone bromide) tablets

2017

- Salix scales up sales force by nearly 40%